<DOC>
	<DOCNO>NCT00926055</DOCNO>
	<brief_summary>18F-fluorodeoxyglucose ( FDG ) positron emission tomography ( PET ) promise tool identify quantify vascular inflammation within atherosclerotic plaque . Therefore , study investigator intend compare effect ezetimibe monotherapy ezetimibe plus statin combination therapy atherosclerosis regression use FDG-PET .</brief_summary>
	<brief_title>Effects Atherosclerosis Regression Ezetimibe Ezetimibe Plus Simvastatin ; Evaluated Fluorodeoxyglucose Positron Emission Tomography ( FDG-PET )</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<mesh_term>Deoxyglucose</mesh_term>
	<criteria>hsCRP &gt; 2 mg/L LDL cholesterol &gt; 130 mm/dL history cardiovascular disease diabetes uncontrolled hypertension active infection previous antihyperlipidemic agent within 6 month previous steroid antiinflammatory agent within 6 month liver disease renal disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>high risk patient atherosclerosis</keyword>
</DOC>